AstraZeneca, Daiichiâs breast cancer drug trials show rise in survival
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team June 3, 2024: An antibody-drug conjugate, jointly being developed by AstraZeneca and Daiichi Sankyo, has been shown in end-stage clinical trials.
Negotiations at reaching a global accord to help fight pandemics better will conclude by 2025 or âearlier if possible at a special session.
Sixty percent of the patients treated with Pfizerâs Lorbrena drug, for a rare form of advanced lung cancer, were alive without disease progression.
Eighteen million people are âacutelyâ hungry in conflict-ridden Sudan as a famine is on the horizon and 800,000 civilians get ready for large-scale.
Technology-based medical training has led to junior doctors avoiding the ward to stick to the electronic tablet â a healthcare crisis that will.
The European Commission has granted marketing approval for Biogen Inc.âs therapy for the treatment of a form of amyotrophic lateral sclerosis.
A dairy farm worker in Michigan, US, has been infected with highly pathogenic avian influenza from sick cows âthe third such case in America.
Johnson & Johnson has agreed to buy the rights for an investigational skin disorder treatment from Numab Therapeutics for $1.25 billion.
The US drug regulator has approved Amenâs biosimilar, Bkemv, to treat rare blood disorders, according to a statement from the Food and Drug.
About 70% of the 4.2 million deaths in 2019 attributed to air pollution were caused by cardiovascular conditions â ischaemic heart disease and.